Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Taxotere and Irinotecan in Advanced NSCLC
NCT00819728Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2000
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Sanofi. Started Jun 2000; status: completed.
02
Drugs
docetaxelirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00819728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00819728.